Asif Habib, MD
Psychiatry · Saint Louis, MONPI 1124000104
Payments from drug & device makers
Across 1,020 payments — averaging $506.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$303K
- Teva Pharmaceuticals USA, Inc.$144K
- Neurocrine Biosciences, Inc.$34K
- Avanir Pharmaceuticals, Inc.$8K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
- Alkermes, Inc.$5K
- plus $15K from 25 others
Across 4 payments — averaging $234.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$937
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $303,417 |
| Teva Pharmaceuticals USA, Inc. | 119 | $144,434 |
| Neurocrine Biosciences, Inc. | 137 | $34,058 |
| Avanir Pharmaceuticals, Inc. | 5 | $8,029 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $6,568 |
| Alkermes, Inc. | 80 | $4,747 |
| Pfizer | 1 | $2,844 |
| Boehringer Ingelheim RCV GmbH & Co KG | 28 | $2,834 |
| Otsuka America Pharmaceutical, Inc. | 160 | $2,351 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 117 | $1,817 |
| AbbVie(2 entities) | 96 | $1,069 |
| Sunovion Pharmaceuticals Inc. | 72 | $996 |
| Lundbeck LLC | 48 | $758 |
| Johnson & Johnson | 31 | $617 |
| Eisai Inc. | 33 | $405 |
| Vanda Pharmaceuticals Inc. | 19 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $374 |
| E.r. Squibb & Sons, L.L.C. | 13 | $319 |
| Acadia Pharmaceuticals Inc | 5 | $122 |
| Merck | 5 | $96 |
| Almatica Pharma LLC | 6 | $94 |
| Jazz Pharmaceuticals Inc. | 5 | $77 |
| Orexo US, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Coloplast | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Bausch Health US, LLC | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
| Neuronetics, Inc. | 1 | $13 |
| Indivior Inc. | 1 | $11 |
How this compares
$516,601 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Saint Louis
- Junaid SyedSaint Louis$8M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mary KimmelSaint Louis$539K
- George GrossbergSaint Louis$521K
- Eric LenzeSaint Louis$271K
- Christopher LoyndSaint Louis$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.